STOCK TITAN

Oncolytics Biotech (ONCY) Financials

ONCY NASDAQ
Trailing 12 months to September 30, 2026
Net Income -$37.3M YoY not available
EPS (Diluted) -$0.30 FY2025 annual
Free Cash Flow -$28.8M YoY not available
Operating Cash Flow -$28.8M YoY not available
Market Cap $47.7M as of Nov 20, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ONCY SEC filings page.

This page shows Oncolytics Biotech, Inc. (ONCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ONCY FY2025

The business converts most operating losses into cash use, but shrinking assets and rising liabilities pushed FY2025 equity below zero.

In FY2025, operating cash flow was -$20.1M against a net loss of $28.8M, so accounting losses largely translated into cash consumption. Free cash flow was -$20.1M, nearly identical to operating cash flow, indicating minimal cash reinvestment beyond operations.

Assets fell 43.5% from FY2024 to FY2025 while liabilities increased 12.4%, a combination that signals contraction funded increasingly by creditors. Equity moved from $3.3M to -$3.8M over the same span, leaving liabilities greater than assets.

SG&A rose 52.6% as R&D fell 13.8%, so the expense mix shifted toward administration rather than scientific spending. Current ratio dropped from 2.5x to 1.1x, narrowing short-term balance-sheet cushion. Reported liquidity equaled 3.1 months of annual operating outflow, while financing cash flow increased 180.8% in FY2025; operations were not self-funded. Shares outstanding rose from 80.0M to 116.1M as the asset base contracted, changing how financing burden is distributed.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Oncolytics Biotech, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

Oncolytics Biotech, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Oncolytics Biotech, Inc. reported a net loss of $28.8M while operations used $20.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$9.7M
YoYn/m
QoQn/m

Oncolytics Biotech, Inc.'s EBITDA was -$9.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$9.7M
YoYn/m
QoQn/m

Oncolytics Biotech, Inc. reported a net loss of $9.7M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.08
YoYn/m
QoQn/m

Oncolytics Biotech, Inc. earned -$0.08 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$6.9M
YoYn/m
QoQn/m

Oncolytics Biotech, Inc. recorded an outflow of $6.9M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$2.4M
YoY-72.6%
QoQ-40.9%

Oncolytics Biotech, Inc. held $2.4M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
136M
QoQ+6.8%

Oncolytics Biotech, Inc. had 136M shares outstanding in Q3 2026. Against the prior quarter it is up 6.8%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

None of these metrics is reported for Q3 2026.

Capital Allocation

R&D Spending
$5.2M
YoY+1.4%
QoQ+20.9%

Oncolytics Biotech, Inc. invested $5.2M in research and development in Q3 2026. This represents an increase of 1.4% from the same quarter a year earlier. Against the prior quarter it is up 20.9%.

Capital Expenditures
$7K
YoY+75.0%
QoQn/m

Oncolytics Biotech, Inc. invested $7K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 75.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Share Buybacks

Not reported for Q3 2026.

ONCY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ONCY quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$5.2M+1.4%$4.3M+122.4%$4.6M+62.6%$3.5M$5.1M$1.9M$2.8MN/A
SG&A Expenses$4.6M+2.4%$5.1M+87.1%$4.7M+112.9%$6.0M$4.5M$2.7M$2.2MN/A
Operating Income-$9.7Mn/m-$9.4Mn/m-$9.3Mn/m-$9.5M-$9.6M-$4.7M-$5.0MN/A
EBITDA-$9.7Mn/m-$9.4Mn/m-$9.3Mn/m-$9.5M-$9.5M-$4.6M-$5.0MN/A
Income Tax-$13Kn/m$101K+65.6%N/AN/A-$181K$61KN/AN/A
Net Income-$9.7Mn/m-$9.4Mn/m-$9.2Mn/m-$8.9M-$9.9M-$5.3M-$4.7MN/A
EPS (Basic)-$0.08n/m-$0.08n/m-$0.08n/mN/A-$0.10-$0.06-$0.06N/A
EPS (Diluted)-$0.08n/m-$0.08n/m-$0.08n/mN/A-$0.10-$0.06-$0.06N/A
Diluted Shares (Avg)128M+26.2%120M+31.6%112M+32.7%N/A101M91M85MN/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

ONCY Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ONCY quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$5.8M$7.7M$8.2M$7.6M-43.5%N/AN/AN/A$13.4M
Current Assets$5.3M$7.1M$7.5M$6.8M-45.0%N/AN/AN/A$12.4M
Cash & Equivalents$2.4M-72.6%$4.1M-61.6%$5.5M-48.4%$5.2M-53.0%$8.9M$10.7M$10.6M$11.1M
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0$0$0$0
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0$0$0$0
Total Liabilities$13.3M$13.8M$13.3M$11.4M+12.4%N/AN/AN/A$10.1M
Current Liabilities$5.9M$5.2M$5.4M$6.1M+24.9%N/AN/AN/A$4.9M
Non-Current Liabilities$7.4M$8.6M$7.9M$5.3M+0.8%N/AN/AN/A$5.2M
Total Equity-$7.5Mn/m-$6.2M-266.7%-$5.1M-237.7%-$3.8M-215.2%-$272K$3.7M$3.7M$3.3M
Retained Earnings-$457.9M-$448.2M-$438.7M-$429.5Mn/mN/AN/AN/A-$400.7M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ONCY Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ONCY quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$6.9Mn/m-$8.1Mn/m-$7.3Mn/m-$6.4M-$4.8M-$4.1M-$4.7MN/A
Depreciation & Amortization$17K0.0%$15K-16.7%$16K-15.8%$16K$17K$18K$19KN/A
Stock-Based Compensation$2.0M-21.2%$2.4M+575.4%$2.3M+172.1%N/A$2.6M$362K$845KN/A
Capital Expenditures$7K+75.0%$0n/m$6K+500.0%$1K$4K$0$1KN/A
Free Cash Flow-$6.9Mn/m-$8.1Mn/m-$7.3Mn/m-$6.4M-$4.8M-$4.1M-$4.7MN/A
Investing Cash Flow-$7Kn/m$0n/m-$6Kn/m-$1K-$4K$0-$1KN/A
Financing Cash Flow$5.2M+69.7%$6.8M+65.4%$7.6M+82.0%$2.8M$3.1M$4.1M$4.2MN/A

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ONCY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ONCY quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on EquityN/AN/AN/AN/AN/A-142.7%-126.5%N/A
Return on Assets-166.4%-123.1%-113.3%-117.3%N/AN/AN/AN/A
Current Ratio0.891.351.381.12-1.4xN/AN/AN/A2.55
Liabilities-to-EquityN/AN/AN/AN/AN/AN/AN/A3.07

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$3.8M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Oncolytics Biotech, Inc. ONCY FY2025 N/A -$28.8M N/A $47.7M —
Verrica Pharmaceuticals Inc. VRCA FY2025 $35.6M -$17.9M -50.3% $47.1M 66/100
RenovoRx, Inc. RNXT FY2025 $1.1M -$11.2M N/A $45.5M 57/100
Annovis Bio, Inc. ANVS FY2025 $0 -$28.9M N/A $44.1M —
Acrivon Therapeutics, Inc. ACRV FY2025 N/A -$77.9M N/A $49.3M —
ImageneBio, Inc. IMA FY2025 $800K -$45.3M N/A $48.8M —

Frequently Asked Questions

No, Oncolytics Biotech, Inc. (ONCY) reported a net loss of $37.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $28.8M.

Oncolytics Biotech, Inc. (ONCY) reported diluted earnings per share of -$0.30 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Oncolytics Biotech, Inc. (ONCY) had EBITDA of -$28.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Oncolytics Biotech, Inc. (ONCY) recorded an outflow of $20.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Oncolytics Biotech, Inc. (ONCY) recorded an outflow of $20.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Oncolytics Biotech, Inc. (ONCY) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Oncolytics Biotech, Inc. (ONCY) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Oncolytics Biotech, Inc. (ONCY) invested $13.3M in research and development during fiscal year 2025.

Oncolytics Biotech, Inc. (ONCY) had 116M shares outstanding as of fiscal year 2025.

Oncolytics Biotech, Inc. (ONCY) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.

Oncolytics Biotech, Inc. (ONCY) had a return on assets of -379.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Oncolytics Biotech, Inc. (ONCY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $47.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Oncolytics Biotech, Inc. (ONCY) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $47.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Oncolytics Biotech, Inc. (ONCY) held $5.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $20.1M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Oncolytics Biotech, Inc. (ONCY) has negative shareholder equity of -$3.8M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Oncolytics Biotech, Inc. (ONCY) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Oncolytics Biotech, Inc. (ONCY) reported a net loss of $28.8M while operations used $20.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top